New Generation Expands In AstraZeneca's Vacated Campus
This article was originally published in Scrip
When AstraZeneca plc decided three years ago to relocate its R&D headquarters from its Alderley Park campus in the Northwest of England to be nearer the biotech action around Cambridge, a research park built to accommodate thousands of scientists suddenly faced the prospect of becoming a ghost town. However, for Dr Neil Murray, CEO of local firm Redx Pharma, the site represents a great opportunity.
You may also be interested in...
After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.